Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The trends in the rationale of chemotherapy for malignant lymphoma are to use combination regimen, non-cross resistant alternating regimen, and hybrid regimen. Long follow-up results of chemotherapy of lymphoma were summarized as follows: for Hodgkin's disease, MOPP regimen of 20 years from NCI in 188 patients (pts) with 84% CR rate and 54% (101 pts) relapse-free (RF) at 15 years, and MOPP-ABV hybrid regimen in 76 pts with 97% CR rate and 90% RFS rate at 7 years; for non-Hodgkin's lymphoma (NHL), results of three generations are reported: the first generations were the first generation (CHOP, BACOP, 40-50s% CR rate and 30s% long-term survivors), the second generation (Pro-MACE/MOPP, 70s% and 40-50s%) and the third generation (MACOP-B, 80s% and 60-70s%). MACOP-B regimen in 125 pts with large-cell lymphoma showed 84% CR rate and 69% RFS rate and 69% RFS rate at 6.5 years. In our studies with four regimens of VCP, AVCP, AVCP/EMLP and B-AVCR/EMVP, CR rate was 56% in 101 pts, and 26 pts are still in CR among 40 living pts. The CR rate and the RSF rate reported in Japan are generally still low for curability of NHL.
 ...
PMID:[Cancer curable by chemotherapy: malignant lymphoma]. 265 23

Phase II-III trials of oral VP 16-213 (VP 16) were conducted in non-Hodgkin lymphoma (NHL) and small cell lung cancer (SCLC). Of 29 heavily pretreated patients (pts) with NHL treated VP 16 at a dose of 200 mg/d days 1-5 q 3w, there were 3 CRs and 6 PRs (CR + PR : 31%) lasting 16 (7-185) weeks. Of 19 pts with NHL in stages III-IV treated by a non-cross alternating regimen consisting of AVCP (ADM, VCR, CPM, PDN)/EMLP (VP 16, MTX, L-ASP PDN), there were 4 CRs (21%) and 14 PRs (74%) lasting a median duration of 4.5 months. A combination consisting of VCR. VP 16 and CPM (VEC) was administered to a total of 29 pts with SCLC. Nine out of 10 pts with LD and 10 out of 19 pts with ED were attained CR after 2 cycles of VEC and subsequent irradiation to primary tumor. A median survival time of CR (LD + ED) exceeded one year while that of PR was 7+ months. These results indicated that oral VP 16 has significant activity for NHL and SCLC and lack of cross resistance to conventional drugs used for NHL.
 ...
PMID:[VP 16-213]. 387 41